CLINICAL TRIALS PROFILE FOR RENVELA

All Clinical Trials for RENVELA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00785629 ↗	A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD	Completed	DaVita Dialysis	N/A	2009-02-01	The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.
NCT00785629 ↗	A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD	Completed	Fresenius Medical Care North America	N/A	2009-02-01	The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.
NCT00785629 ↗	A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD	Completed	Genzyme, a Sanofi Company	N/A	2009-02-01	The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.
NCT00785629 ↗	A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD	Completed	Novartis Pharmaceuticals	N/A	2009-02-01	The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.
NCT00785629 ↗	A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD	Completed	Shire	N/A	2009-02-01	The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.
NCT00785629 ↗	A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD	Completed	Denver Nephrologists, P.C.	N/A	2009-02-01	The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.

Clinical Trial Conditions for RENVELA

Condition Name

Condition Name for RENVELA
Intervention	Trials
Hyperphosphatemia	9
Chronic Kidney Disease	6
Healthy	2
Insulin Sensitivity	2

Condition MeSH

Condition MeSH for RENVELA
Intervention	Trials
Kidney Diseases	15
Renal Insufficiency, Chronic	13
Hyperphosphatemia	10
Kidney Failure, Chronic	7

Clinical Trial Locations for RENVELA

Trials by Country

Trials by Country for RENVELA
Location	Trials
United States	85
China	14
Puerto Rico	3
Denmark	2
Italy	2

Trials by US State

Trials by US State for RENVELA
Location	Trials
New York	8
California	6
Texas	6
Colorado	5
Illinois	4

Clinical Trial Progress for RENVELA

Clinical Trial Phase

Clinical Trial Phase for RENVELA
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	8
Phase 2	7

Clinical Trial Status

Clinical Trial Status for RENVELA
Clinical Trial Phase	Trials
Completed	23
Recruiting	2
Terminated	2

Clinical Trial Sponsors for RENVELA

Sponsor Name

Sponsor Name for RENVELA
Sponsor	Trials
Genzyme, a Sanofi Company	7
Shire	3
Fresenius Medical Care North America	2

Sponsor Type

Sponsor Type for RENVELA
Sponsor	Trials
Industry	26
Other	20
NIH	1